Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Rating of “Moderate Buy” by Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $56.00.

AGIO has been the subject of a number of recent analyst reports. Bank of America decreased their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. Scotiabank decreased their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a report on Monday, July 28th. Wall Street Zen lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 19th. Finally, HC Wainwright restated a “buy” rating and issued a $56.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, September 4th.

Agios Pharmaceuticals Stock Performance

AGIO stock opened at $36.50 on Friday. The firm has a 50 day moving average price of $37.70 and a 200-day moving average price of $33.25. Agios Pharmaceuticals has a 52-week low of $23.42 and a 52-week high of $62.58. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of 3.32 and a beta of 0.87.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The business had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.46 million. As a group, sell-side analysts forecast that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,770 shares of the business’s stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $92,905.80. Following the completion of the sale, the insider directly owned 26,122 shares in the company, valued at approximately $876,131.88. The trade was a 9.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Brian Goff sold 18,700 shares of the business’s stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $627,198.00. Following the sale, the chief executive officer owned 105,401 shares of the company’s stock, valued at approximately $3,535,149.54. This represents a 15.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 65,994 shares of company stock worth $2,341,232 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new stake in Agios Pharmaceuticals during the 4th quarter valued at $39,000. NewEdge Advisors LLC purchased a new stake in Agios Pharmaceuticals during the 1st quarter valued at $40,000. CWM LLC raised its stake in Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 996 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Agios Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 320 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in Agios Pharmaceuticals by 16.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 499 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.